Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576699 | PMC |
| http://dx.doi.org/10.1007/s11606-024-08977-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Impact of dronabinol shortage on a population of chronic pain patients: A retrospective observational study].
Therapie
January 2025
Service de pharmacie clinique, pôle 8 cancérologie et spécialités médicales, centre hospitalier de Valenciennes, 59300 Valenciennes, France.
Objective: A supply shortage of dronabinol occurred between December 2023 and February 2024, forcing chronic pain patients to discontinue this treatment. We assessed the impact of this shortage on patients in our hospital.
Method: A retrospective observational study of patients treated with dronabinol was conducted.
A systematic review on risk factors and reasons for e-cigarette use in adolescents.
Tob Induc Dis
January 2025
Faculty of Health Sciences, Valencian International University, Valencia, Spain.
Introduction: The aim was to establish EC use risk and protective factors, the reasons for use, associations with tobacco and other substance use, and use for smoking cessation.
Methods: A systematic review following PRISMA guidelines was registered in PROSPERO (CRD42024532771). Searches in Web of Science and PubMed/MEDLINE (March-April 2024) used terms like 'electronic cigarette' and 'adolescents' with a PICO framework.
Lebanese Cannabis sativa L. extract protects from cisplatin-induced nephrotoxicity in mice by inhibiting podocytes apoptosis.
J Cannabis Res
January 2025
School of Pharmacy, Pharmaceutical Sciences Department, Lebanese American University, Byblos, Lebanon.
Background: Cisplatin is an anti-cancer drug used to treat a plethora of solid tumors. However, it is associated with dose dependent nephrotoxicity limiting its use as anticancer agent.
Objective: The current study aimed to investigate the nephroprotective effect of native Lebanese Cannabis sativa in both in vitro and in vivo mice model of cisplatin-induced nephrotoxicity.
Weight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.
Diabetes Metab
January 2025
Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium; Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Electronic address:
Background: Obesity is an increasing public health problem because of its high prevalence and associated morbidity and mortality. Two weight-loss strategies are currently used, either bariatric surgery or pharmacological therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs). Preclinical studies in rodents suggested an increased risk of additive disorders after bariatric surgery contrasting with a reduced risk with GLP-1RAs.
View Article and Find Full Text PDFReducing medical cannabis use risk among Veterans: A descriptive study.
Harm Reduct J
January 2025
Department of Psychology, Memorial University of Newfoundland, St. John's, NL, Canada.
Background: Canadian Veterans experiencing chronic pain report concerns about accessing accurate information on the risks associated with medical cannabis (MC) use. The Lower Risk Cannabis Use Guidelines (LRCUG) were developed to equip individuals who use cannabis recreationally with safer-use strategies. Many of the harm reduction recommendations for recreational cannabis use are relevant and important considerations for MC use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!